

TB Saracen UK Alpha Fund

April 2020

SARACEN
share success

Signatory of:



Fund Overview

- Objective: to achieve a higher rate of return than the MSCI UK All Cap Index by investing in a portfolio of primarily UK equity securities with the potential for long term growth.
- The portfolio has a bias towards small and medium sized companies and a high active share compared to the benchmark.
- The fund has significant capacity and liquidity at a competitive annual charge.
- The Fund recently celebrated its 20th anniversary and, since launch in March 1999, has outperformed its benchmark in 16 out of 20 years and in 8 out of the last 10 calendar years.
- A concentrated portfolio of 25-35 holdings, with a focus on capital growth, backed by the Saracen research process.

Performance Chart*

5 Year Performance (%)

— TB Saracen UK Alpha Fund B Acc
— MSCI UK All Cap Index (TR)



*Source: Bloomberg, as at 30th April 2020

Total Return, Bid to Bid, GBP terms. Past performance is not a reliable indicator of future results. The value of your investment and the income derived from it can go down as well as up and you may not get back the money you invested.

Cumulative Performance after all charges to 30th April 2020

	1 month	3 months	1 year	3 years	5 years	Since launch*
TB Saracen UK Alpha B Acc	13.6%	-28.9%	-20.5%	-9.3%	10.2%	529.0%
MSCI UK All Cap Index (TR)	4.5%**	-19.3%	-17.9%	-9.0%	2.7%	
Sector Average	10.3%	-18.5%	-14.6%	-7.2%	6.3%	143.0%
Quartile Ranking	1	4	4	3	2	1

Source: Financial Express; *launch date 05 March 1999

Sector: IA Sector (UK All Companies)

** Note – the MSCI AllCap Index fell by 2.5% after our 12 noon pricing point on 30th April 2020. Index returns shown are at market close.

FOR PROFESSIONAL INVESTORS ONLY

Retail investors should consult their financial advisers

FUND DETAILS

(as at 30th April 2020)

Fund size: £10.4m
Launch date: 05/03/99

No. of holdings: 30
Active share: 92%
Source: Bloomberg

Denomination: GBP

Valuation point: 12 noon

Fund prices:

A Accumulation: 383.19p
B Accumulation: 628.97p

Policy is not to charge a dilution levy except in exceptional circumstances.

ACD:

T. Bailey Fund Services Limited

Scott McKenzie
Fund Manager

David Clark
Fund Manager



Scott McKenzie joined Saracen in August 2014 and has managed the fund since June 2017. **David Clark** joined the team in March 2019. Both David and Scott have over 25 years' experience managing UK equity funds.



TB Saracen UK Alpha Fund


April 2020

SARACEN
share success

Signatory of:



Fund Breakdown by Market Capitalisation



Data as of 30th April 2020 Source: Saracen Fund Managers

Monthly Commentary

Market Background

After the difficulties of March, we were able to report some initial recovery in our fortunes during April. The coronavirus crisis continues unabated with the majority of affected countries still in lockdown and no clear end in sight. However, investors are beginning to adjust to a 'new normal' and look towards recovery of sorts in 2021. Whilst this could be premature it led to significant bounces in some value stocks and small and midcap companies in particular, all of which allowed the Fund to show some good recovery. Significant numbers of companies continued to cut or defer dividends in April, most notably Royal Dutch Shell, where dividends were cut by 66%.

Performance

Having suffered during March the Fund captured the market bounce and more, rising by 13.6% compared to the UK index return of 7.6% (adjusted for noon pricing). At a size level, mid and small cap indices enjoyed rallies of 9.2% and 10.1% respectively while the FTSE100 lagged considerably.

We had 8 stocks which recovered by more than 20%, albeit from very low bases, with the best recoveries seen in small and midcap businesses. Housebuilders were a key positive for the Fund with both MJ Gleeson and Vistry rising by over 40%. Adding to Intermediate Capital and Halfords during March has also significantly improved performance during April. Alpha FMC had a strong recovery, rising by 54%, as did Clinigen, up 33%. STV was our main laggard, falling 26% after holding up in March, whilst both Equiniti and Kin & Carta drifted in response to lacklustre trading updates.

Portfolio Activity

There were no outright sales or purchases. We added to two industrial businesses, Melrose and Johnson Matthey, and we also added to Barclays and Premier Miton in the financials space. We see all four stocks as being currently very oversold. We reduced our holdings in DiscoverIE and Synthomer, both of which had held up well and also took advantage of a strong recovery in Alpha FMC to trim the holding there. Cash held is currently 4%.

April – Attribution *

Top Contributors	Positive
MJ Gleeson	+1.71%
Alpha FMC	+1.71%
Vistry Group	+1.26%
Halfords	+1.15%
Clinigen	+1.05%
Top Detractors	Negative
STV Group	-0.96%
Eurocell	-0.22%
Equiniti	-0.20%
Kin & Carta	-0.06%
Rio Tinto	-0.01%

*Source: Bloomberg as at 30/4/20

Fund Breakdown

Top 10 Holdings	
MJ Gleeson	5.1%
Barclays	4.8%
Standard Life Aberdeen	4.5%
Imperial Brands	4.5%
Rio Tinto	4.3%
Johnson Matthey	4.0%
Vistry	3.9%
Prudential	3.9%
Synthomer	3.9%
Clinigen	3.8%

Sector breakdown	
Financials	27.2%
Industrials	25.0%
Consumer Goods	17.9%
Basic Materials	12.0%
Consumer Services	8.0%
Healthcare	3.8%
Oil & Gas	2.4%
Telecoms	0.0%
Technology	0.0%
Utilities	0.0%

	ISIN	SEDOL	Bloomberg	EMX	Initial Charge	Annual Charge	Ongoing * Charge
B Acc Shares	GB0005711196	0571119	SFMGRBA LN	SARGFB	0%	0.75%	1.19%

* Source: T Bailey Fund Services Ltd.

To place a deal or for further information contact:

T. Bailey Fund Services Limited (TBFS)
64 St. James's Street
Nottingham
NG1 6FJ

General Enquiries: 0115 988 8200
Dealing Line: 0115 988 8274
E-mail Dealing: clientservices@tbailey.co.uk

(Phone and email deals will only be accepted on completion of initial account set up and by prior agreement with TBFS)

T. Bailey Fund Services Limited is authorised and regulated by the Financial Conduct Authority (No. 190293).

Platform Partners



Important information:

This information should not be construed as an invitation, offer or recommendation to buy or sell investments, shares or securities or to form the basis of a contract to be relied on in any way and is by way of information only. Taxation levels, benefits and reliefs may all vary depending on individual circumstances and are subject to change. This document represents the views of Saracen Fund Managers Limited at the time of writing. Subscriptions will only be received, and shares issued on the basis of the current Prospectus, Key Investor Information Document (KIID) and Supplementary Information Document (SID). These are available, in English, together with information on how to buy and sell shares, on-line at: www.tbaileyfs.co.uk.

Risk factors you should consider before investing:

The value of investments and the income from them may go down as well as up and you may get back less than the amount invested. **Past performance is not a guide to future performance.** A full list of the risks applicable to this Fund can be found in the Prospectus. All fund performance figures calculated on a single price basis. This Fund may not be appropriate for investors who plan to withdraw their money in the short-term (within 5 years). The Fund should be viewed as a medium to long-term investment only.

Investment Manager:

Saracen Fund Managers Ltd, 19 Rutland Square, Edinburgh, EH1 2BB. Tel: 0131 202 9100 and on-line at www.saracenfundmanagers.com. Saracen Fund Managers Limited is authorised and regulated by the Financial Conduct Authority. Registered in Scotland No. 180545.

Issued by Saracen Fund Managers Limited. Please note that Saracen Fund Managers Limited do not provide financial advice. If you have any doubt whether the TB Saracen UK Alpha Fund is suitable for you and you wish to receive advice you should contact your Financial Adviser.

Regulatory Status:

FCA Recognised: Yes
Scheme Type: OEIC (UCITS)

Issue date – 30th April 2020